Grifols (GRFS) Short-term Investments (2009 - 2025)
Grifols' (GRFS) quarterly Short-term Investments came in at $41.9 million in Q4 2025, down 83.93% YoY from $260.7 million in Q4 2024, and down 83.93% on a QoQ basis from $260.7 million in Q4 2024.
Grifols (GRFS) Short-term Investments (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Short-term Investments data on file, last reported at $41.9 million in Q4 2025.
- Quarterly Short-term Investments fell 83.93% year-over-year to $41.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $41.9 million (down 83.93% YoY) and the FY2025 annual result came in at $41.9 million, down 83.93% from the prior year.
- Short-term Investments retreated to $41.9 million in Q4 2025, from $260.7 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $260.7 million in Q4 2024 to a low of $3.7 million in Q4 2021.
- A 5-year average of $75.3 million and a median of $41.9 million in 2025 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2022 — Short-term Investments surged 1102.62% — and 2025, when it tumbled 83.93%.
- Tracing GRFS's Short-term Investments over 5 years: stood at $3.7 million in 2021, then surged by 1102.62% to $44.5 million in 2022, then tumbled by 42.89% to $25.4 million in 2023, then surged by 924.93% to $260.7 million in 2024, then plunged by 83.93% to $41.9 million in 2025.
- The last three Short-term Investments figures came in at $41.9 million (Q4 2025), $260.7 million (Q4 2024), and $25.4 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 41.91 Mn |
| Dec 31, 2024 | 260.74 Mn |
| Dec 31, 2023 | 25.44 Mn |
| Dec 31, 2022 | 44.55 Mn |
| Dec 31, 2021 | 3.70 Mn |
| Dec 31, 2020 | 13.26 Mn |
| Sep 30, 2020 | 14.35 Mn |
| Mar 31, 2020 | 14.39 Mn |
| Dec 31, 2019 | -610.45 Mn |
| Sep 30, 2019 | 3.08 Mn |
| Mar 31, 2019 | 202.58 Mn |
| Dec 31, 2018 | 61.60 Mn |
| Sep 30, 2018 | 59.78 Mn |
| Jun 30, 2018 | -477.21 Mn |
| Mar 31, 2018 | 12.92 Mn |
| Dec 31, 2017 | 12.64 Mn |
| Jun 30, 2017 | 2.15 Bn |
| Dec 31, 2016 | 2.79 Mn |
| Sep 30, 2016 | -443.57 Mn |
| Jun 30, 2016 | 363.82 Mn |